Fluoroquinolone resistance and mutation patterns in gyrA and parC genes in Neisseria gonorrhoeae isolates from Shanghai, China

Abstract

In order to study the resistance of Neisseria (N.) gonorrhoeae to the fluoroquinolone and detect mutation patterns of quinolone resistance-determining regions (QRDRs) of clinical isolates in Shanghai, China, a total of 80 clinical isolates of N. gonorrhoeae were consecutively collected from Shanghai. The MIC of fluoroquinolone for the isolates was examined by using the agar dilution method and the mutation profiles of the QRDRs of gyrA and parC were analyzed by sequencing and restriction fragment length polymorphism (RFLP). Chi-square test was used for comparison of the mutation patterns. The results showed that: (1) High percentages of the 8 isolates were resistant to ciprofloxacin (95.0%), ofloxacin (95.0%) and lomefloxacin (97.5%), only one strain was susceptible to the ciprofloxacin. (2) Sensitive strains had a substitute of Asp95→Ala in the gyrA, and all isolates that were resistant or intermediated to the ciprofloxacin, had a double mutation in the gyrA (Ser91, Ala 92 and Asp95). Some strains also had a mutation in the parC. (3) The MICs of these isolates were significantly associated with the mutation patterns in the gyrA and parC. A double mutation of gyrA combined with parC87 mutation was a predominant pattern in Shanghai and could mediate high level resistance to ciprofloxacin. It suggests that mutations in the QRDRs of gyrA and parC may be responsible for the fluoroquinolone resistance. And fluoroquinolone could not be used as the first line antibiotics for gonorrhea treatment any more in Shanghai, China.

Keywords

Neisseria gonorrhoeae / resistance / fluoroquinolone / gyrA / parC

References

[1] The WHO western pacific region Gonococcal Antimicrobials surveillance program.. Annual report of the Australian gonococcal surveillance program 2002. Commun Dis Intell, 2003, 27: 488-491

[2] KnappJ.S., FoxK.K., TreesD.L., et al. . Fluoroquinolone resistance in neisseria gonorrhoeae. Emerging Infectious Disease, 1997, 3: 33-39

[3] BorgenK, LooI, KoedijkF, et al. . Increase of gonococcal quinolone resistance in the Netherlands from 2002–2004. Euro Surveill, 2005, 10(11E051117

[4] YangY., LiaoM., GuW.M., et al. . Antimicrobial susceptibility and molecular determinants of quinolone resistance in Neisseria gonorrhoeae isolates from Shanghai. J Antimicrob Chemother, 2006, 58(4): 868-872

[5] Center for Disease Controlprevention.. Increase in the fluoroquinolone-resistance Neisseria gonorrhoeae among who have sex with men —United States, 2003, and revised recommendation for gonorrhea treatment, 2004. Morb Mortal Wkly Rep, 2004, 53: 335-338

[6] BellandR.J., MorrisonS.G., IsonC.A., et al. . Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol Microbiol, 1994, 1: 371-380

[7] CorkillJ.E., PercivalA., LindM.. Reduced uptake of ciprofloxacin in a resistance strain of Neisseria gonorrhoeae and transformation of resistance to other strains. J Antimicrob Chemother, 1991, 28: 601-604

[8] UthmanA., Heller-VitouchC., StaryA., et al. . High-frequency of quinolone-resistant Neisseria gonorrhoeae in Austria with a common pattern of triple mutations in GyrA and ParC genes. Sex Transm Dis, 2004, 31(10): 616-618

[9] DeguchiT., YasudaM., NakanoM., et al. . Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles. Antimicrob Agents Chemother, 1996, 40(4): 1020-1023

[10] National Committee for Clinical Laboratory Standards.. Performance Standards for Antimicrobial Susceptibility Testing: Twelfth International Supplement. M100-S12, 2002, Wayne, PA, NCCLS: 53-55

[11] DeguchiT., YasudaM., AsanoM., et al. . DNA gyrase mutations in quinolone-resistant clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother, 1995, 39(2): 561-563

[12] TreesD.L., SandulA.L., WhittingtonW.L., et al. . Identification of novel mutation patterns in the parC gene of ciprofloxacin-resistant isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother, 1998, 42(8): 2103-2105

[13] GransdenW.R., WarrenC.A., PhillipsI., et al. . Decreased susceptibility of Neisseria gonorrhoeae to ciprofloxacin. Lancet, 1990, 335(8680): 51

[14] Center for Disease Controlprevention.. Increase in fluoroquinolone-resistance Neisseria gonorrhoeae — Hawaii and California, 2001. Morb Mortal Wkly Rep, 2002, 51(46): 1041-1044

[15] TanakaM., NakayamaH., HaraokaM., et al. . Antimicrobial resistance of Neisseria gonorrhoeae and high prevalence of ciprofloxacin-resistant isolates in Japan, 1993 to 1998. J Clin Microbiol, 2000, 38: 521-525

[16] RayK., BalaM., KumarJ., et al. . Trend of antimicrobial resistance in Neisseria gonorrhoeae at New Delhi, India. Int J STD AIDS, 2000, 11: 115-118

[17] The WHO Western Pacific Gonococccal Antimicrobial Surveillance Program.. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2003. Commun Dis Intell, 2005, 29(1): 62-64

[18] The WHO Western Pacific Gonococccal Antimicrobial Surveillance Program.. The Gonococcal Antimicrobial Surveillance Programme (GASP). WHO western Pacific region, 1995. Wkly Epidemiol Rec, 1997, 72(5): 25-27

[19] GilesJ.A., FalconioJ., YuengerJ.D., et al. . Quinolone resistance-determining region mutations and por type of Neisseria gonorrhoeae isolates: resistance surveillance and typing by molecular methodologies. J Infect Dis, 2004, 189(11): 2085-2093

[20] WangS.C., LiuY.F., SuM.Q., et al. . Correlation of in vitro susceptibilities to quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains isolated with changes in gyrA and parC in China. Di 4 Jun Yi Da Xue Xue Bao (Chinese), 2001, 22(24): 2257-2261

[21] KamK.M., KamS.S., CheungD.T., et al. . Molecular characterization of quinolone-resistant Neisseria gonorrhoeae in Hong Kong. Antimicrob Agents Chemother, 2003, 47(1): 436-439

[22] ZouM.X., XiaZ.D., ChenS.Z., et al. . Correlation between fluoroquinolone resistance and mutations of Neisseria gonorrhoeae gyrA and parC genes. Chin J Dermatol (Chinese), 2002, 35(3): 199-202

[23] Shigemura K, Shirakawa T, Okada H, et al. Mutations in the gyrA and parC genes and in vitro activities of fluoroquinolones in 91 clinical isolates of Neisseria gonorrhoeae in Japan. Sex Transm Dis, 2004,31(3):180–184

[24] LindbackE.M., RahmanS., JalalS., et al. . Mutations in gyrA, gyrB, parC and parE in quinolone-resistance strains of Neisseria gonorrhoeae. APMIS, 2002, 110(9): 651-657